ALT Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.

ALT Graph depicting survival rates over time for patients using selpercatinib versus a placebo in early-stage RET fusion-positive non-small-cell lung cancer. The x-axis shows months since randomization, and the y-axis represents the percentage of patients. The logo for the New England Journal of Medicine is present.

ALT This image shows three Kaplan-Meier survival curves comparing talazoparib plus enzalutamide versus placebo plus enzalutamide across different subgroups over months. Each graph represents a different subgroup: Intention-to-Treat Population, BRCA Subgroup, and Non-BRCA Subgroup. The x-axis is in months, and the y-axis represents the percentage of patients. Data points are annotated with the number of events and median imaging-based progression-free survival times.

ALT A four-panel graph illustrating the secondary efficacy end points. Panel A shows overall survival, with a line graph comparing talazoparib–enzalutamide and placebo–enzalutamide over 56 months. Panel B displays a line graph of confirmed PSA progression. Panel C features a line graph detailing subsequent antineoplastic therapy. Panel D is a bar graph depicting the objective response, with categories for complete response, partial response, stable disease, and progression, comparing both treatment groups.